To evaluate the efficacy and safety of intravitreal 0.7-mg dexamethasone implant (DEX-I) (Ozurdex®) in the treatment of extensive exudative retinal detachment (RD) associated with uveal melanoma treated using proton beam therapy (PBT).
Data from 10 patients with exudative RD after PBT treated with intravitreal injection of 0.7-mg DEX-I were reviewed retrospectively. The main outcome measures were resolution of exudative RD, visual acuity, and safety profile.
Mean age was 55.6 years (range 34-85). Mean time between PBT and DEX-I was 12.4 months (range 3-25). Mean follow-up was 9.9 months (range 4-15). Intravitreal Ozurdex® reduced exudative RD in 7 cases (70%) on average 3.1 months after injection with complete resolution of RD in 6 of these (60%). For half of the patients, their level of vision remained stable; the other half experienced a deterioration in visual acuity at the end of follow-up. No adverse effects were observed.
In this small case series, treatment with intravitreal DEX-I reduced exudative RD in the majority of cases and had an acceptable safety profile.
Eur J Ophthalmol 2017; 27(5): 596 - 600
Article Type: ORIGINAL RESEARCH ARTICLE
AuthorsAriane Malclès, Anh-Minh Nguyen, Thibaud Mathis, Jean-Daniel Grange, Laurent Kodjikian
- • Accepted on 15/01/2017
- • Available online on 08/02/2017
- • Published in print on 30/08/2017
This article is available as full text PDF.
- Malclès, Ariane [PubMed] [Google Scholar]
- Nguyen, Anh-Minh [PubMed] [Google Scholar]
- Mathis, Thibaud [PubMed] [Google Scholar]
- Grange, Jean-Daniel [PubMed] [Google Scholar]
- Kodjikian, Laurent [PubMed] [Google Scholar] , * Corresponding Author (firstname.lastname@example.org)
Department of Ophthalmology, Croix-Rousse University Hospital, Hospices Civils de Lyon, University of Medicine Lyon 1, Lyon - France